Novanta just made a $1.2bn surgical consumables bet. Can Riverpoint justify the price?
Novanta completes Riverpoint Medical acquisition, expanding surgical consumables and recurring revenue. See what integration and returns must deliver.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Why Novanta’s June healthcare conference appearance matters after its Q1 revenue rebound
Medtech suppliers are under pressure to prove growth quality. Novanta’s Jefferies appearance may sharpen the investor debate.